PMID- 26246248
OWN - NLM
STAT- MEDLINE
DCOM- 20160616
LR  - 20191113
IS  - 2212-3970 (Electronic)
IS  - 1574-8928 (Linking)
VI  - 10
IP  - 3
DP  - 2015
TI  - "Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in 
      EGFR Mutated Patients: A Short-Term Cohort Study.
PG  - 342-51
AB  - BACKGROUND: Erlotinib is a validated drug "for the treatment of patients affected 
      by advanced unresectable non small cell lung cancer (NSCLC) with EGFR mutations". 
      We want to focus on potential functional benefits deriving from a combined 
      therapy containing TKI (erlotinib) and a nicotinic partial agonist 
      (varenicicline) in smokers. METHODS: we analyzed the records of patients affected 
      by NSCLC treated undergoing "first line therapy with Erlotinib" and smoking 
      cessation (with varenicicline). Response to therapy was evaluated by CT scan. 
      Data concerning clinical history, smoking habit, nicotine dependence were 
      collected after three months from the beginning of the recruitment. Pulmonary 
      function tests including spirometry with pletismographic technique and exhaled 
      carbon monoxide (CO) were performed with recording of resistances, flows, 
      volumes. A group of ten current smokers affected by NSCLC with EGFR activating 
      mutation and concurrent mild COPD undergoing anti-EGFR treatment without smoking 
      cessation was used to compare clinical and functional data. A control group of 
      NSCLC wild type with mild COPD undergoing smoking cessation was assessed for 
      functional data. RESULTS: Twenty-five patients were enrolled. All of them 
      reported partial response at CT re-evaluation. All functional indexes and 
      parameters were improved after combined treatment a significant increase of FEV1 
      level and a decrease of exhaled CO. In particular, a mean increase of FEV1 from 
      1.93 (SD 0.48) to 2.03(SD 0.46) liters was recorded. A notable reduction of sRAW 
      (specific resistances) was also observed. The improvement of some parameters such 
      as CO, heart rate (HR), sRAW and FEV1 resulted statistically significant. A 
      better response to therapy was found "in the study group compared to the second 
      group of mutated NSCLC patients". In this second group, we also observed an 
      improvement of functional obstructive parameters although it was less remarkable 
      than study group. Only sRAW and FEF 25/75 were significantly increased. The group 
      of NSCLC wild type undergoing only smoking cessation showed a lower increase of 
      FEV1 by about 50 ml compared to the first group. CONCLUSION: The combination of 
      anti-EGFR treatment and concurrent therapy for smoking cessation seems to be more 
      effective than erlotinib alone in improving lung function and clinical response 
      in advanced NSCLC patients with EGFR-mutations. It is conceivable that erlotinib 
      may potentiate the action of varenicline. We have also outlined some relevant 
      patents concerning varenicline and EGFR-TKI.
FAU - Pezzuto, Aldo
AU  - Pezzuto A
FAU - Stumbo, Luciano
AU  - Stumbo L
FAU - Russano, Marco
AU  - Russano M
AD  - Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro 
      del Portillo 200, 00128 Rome, Italy. m.russano@unicampus.it.
FAU - Crucitti, Pierfilippo
AU  - Crucitti P
FAU - Scarlata, Simone
AU  - Scarlata S
FAU - Caricato, Marco
AU  - Caricato M
FAU - Tonini, Giuseppe
AU  - Tonini G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United Arab Emirates
TA  - Recent Pat Anticancer Drug Discov
JT  - Recent patents on anti-cancer drug discovery
JID - 101266081
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Nicotinic Agonists)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - W6HS99O8ZO (Varenicline)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/complications/*drug therapy/genetics
MH  - Erlotinib Hydrochloride/*therapeutic use
MH  - Female
MH  - Forced Expiratory Volume
MH  - Genes, erbB-1/*genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Nicotinic Agonists/therapeutic use
MH  - Respiratory Function Tests
MH  - Smoking/adverse effects
MH  - *Smoking Cessation/methods
MH  - Treatment Outcome
MH  - Varenicline/therapeutic use
EDAT- 2015/08/08 06:00
MHDA- 2016/06/17 06:00
CRDT- 2015/08/07 06:00
PHST- 2015/03/26 00:00 [received]
PHST- 2015/07/28 00:00 [revised]
PHST- 2015/08/04 00:00 [accepted]
PHST- 2015/08/07 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2016/06/17 06:00 [medline]
AID - PRA-EPUB-69357 [pii]
AID - 10.2174/1574892810666150806111014 [doi]
PST - ppublish
SO  - Recent Pat Anticancer Drug Discov. 2015;10(3):342-51. doi: 
      10.2174/1574892810666150806111014.